{
  "meta": {
    "title": "Demyelinating_Disorders_Of_Nervous_System",
    "url": "https://brainandscalpel.vercel.app/demyelinating-disorders-of-nervous-system-a85dea7f.html",
    "scrapedAt": "2025-11-30T08:49:02.545Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Guillain-Barre Syndrome</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Sclerosis</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Myasthenia Gravis</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Amyotrophic Lateral Sclerosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old female patient presents with recurrent episodes of numbness in her limbs, visual blurring in her right eye, and muscle weakness. She reports that these symptoms have been episodic over the past year. On examination, sensory deficits are noted, and there is evidence of optic neuritis. Based on the symptoms, what is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295021",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295021,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Multiple Sclerosis (MS)</strong> is a chronic demyelinating disease that commonly presents with episodic neurological symptoms, including <strong>sensory loss (37% of cases), optic neuritis (36% of cases), and muscle weakness (35% of cases)</strong>, as seen in this patient.</li>\r\n<li><strong>Optic neuritis</strong> is a hallmark symptom often associated with MS, presenting as visual blurring or loss, commonly in one eye.</li>\r\n<li><strong>Sensory loss and weakness</strong> are among the most frequent initial presentations of MS, aligning with the patient's reported symptoms.</li>\r\n</ul>\r\n<p><strong>Why Other Options Are Incorrect:</strong></p>\r\n<p><strong>Option A: Guillain-Barr&eacute; Syndrome (GBS):</strong> Typically presents with an ascending pattern of weakness and areflexia, without optic neuritis or episodic symptoms.</p>\r\n<p><strong>Option C: Myasthenia Gravis:</strong> Presents with fatigable weakness, especially affecting ocular muscles, but does not cause sensory loss or optic neuritis.</p>\r\n<p><strong>Option D: Amyotrophic Lateral Sclerosis (ALS):</strong> Usually presents with progressive weakness without sensory symptoms, optic neuritis, or episodic nature.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Multiple Sclerosis</strong> often presents with <strong>episodic neurological symptoms</strong>, including <strong>sensory loss, optic neuritis, and muscle weakness.</strong></li>\r\n<li><strong>Optic neuritis</strong> is strongly associated with MS and is one of the initial manifestations in many cases.</li>\r\n<li>MS symptoms vary widely, but <strong>sensory loss</strong> and <strong>visual disturbances</strong> are the most common initial presentations.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501066ef02631-e489-459e-bff3-03e17cec0842.jpg\">",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Optic neuritis with visual blurring, often monocular</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Muscle weakness accompanied by upper motor neuron signs</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Persistent, severe hearing loss as a primary symptom</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Ataxia and cerebellar dysarthria affecting coordination</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 29-year-old female presents with multiple neurological complaints over the past year, including episodes of blurred vision in her left eye, weakness in her right arm, and difficulty with balance. She also reports intermittent numbness in her legs and occasional muscle spasms in her lower limbs, which worsen with activity. On examination, she has an afferent pupillary defect in the left eye, hyperreflexia, and a positive Babinski sign. Based on the typical clinical presentation of the diseases which of the following is NOT commonly associated with it?</span></p>",
      "unique_key": "DT1295025",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295025,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Option A: Optic Neuritis with Visual Blurring, Often Monocular</strong></p>\r\n<p>Optic neuritis (ON) is a classic symptom in MS and often presents with monocular visual impairment, such as blurring or decreased color perception (desaturation) in the central field of vision. Patients frequently experience <strong>periorbital pain</strong>, which worsens with eye movement. An <strong>afferent pupillary defect</strong> is typically observed in the affected eye.</p>\r\n<p><strong>Diagnostic Note</strong>: Optic neuritis is highly specific to demyelinating conditions like MS. MRI may reveal lesions in the optic nerve, supporting the diagnosis.</p>\r\n<p><strong>Option B: Muscle Weakness Accompanied by Upper Motor Neuron Signs</strong></p>\r\n<p>Weakness in MS typically stems from lesions in the corticospinal tract, leading to <strong>upper motor neuron (UMN) signs</strong> such as spasticity, hyperreflexia, and a positive <strong>Babinski sign</strong>. The weakness may be exacerbated by physical activity (exercise-induced weakness), which is characteristic in MS and is often due to conduction block in demyelinated neurons.</p>\r\n<p><strong>Diagnostic Note</strong>: UMN signs differentiate MS-related weakness from conditions like peripheral neuropathy or myopathy, which typically show lower motor neuron or muscle-specific signs.</p>\r\n<p><strong>Option C: Persistent, Severe Hearing Loss as a Primary Symptom</strong></p>\r\n<p><strong>Hearing loss is uncommon</strong> in MS and, when present, is usually mild and transient, related to lesions in the auditory pathways within the brainstem. Persistent, severe hearing loss is atypical and should raise suspicion for other causes, such as acoustic neuroma, chronic infections, or autoimmune diseases affecting the auditory system.</p>\r\n<p><strong>Diagnostic Note</strong>: If a patient with suspected MS presents with significant hearing loss, alternative diagnoses should be considered, possibly warranting further imaging or auditory testing to rule out other conditions.</p>\r\n<p><strong>Option D: Ataxia and Cerebellar Dysarthria Affecting Coordination</strong></p>\r\n<p><strong>Ataxia</strong> and <strong>cerebellar dysarthria</strong> (scanning speech) are common symptoms in MS due to involvement of the cerebellum and its pathways. Ataxia can affect the limbs, trunk, and gait, leading to imbalance and uncoordinated movements. Tremors, especially <strong>intention tremors</strong>, may be present when cerebellar pathways are affected.</p>\r\n<p><strong>Diagnostic Note</strong>: The presence of ataxia, particularly if associated with tremor and dysarthria, supports MS, as these symptoms often stem from demyelination in the cerebellum or its connections.</p>\r\n<p><strong>Key Takeaways for MS Symptoms</strong></p>\r\n<ul>\r\n<li><strong>Optic neuritis, muscle weakness, sensory loss, and cerebellar signs</strong> are key presenting features of MS.</li>\r\n<li>MS symptoms are often <strong>episodic or relapsing-remitting</strong>, distinguishing it from more progressive neurological disorders.</li>\r\n<li><strong>Less typical symptoms</strong> (e.g., severe hearing loss, persistent uveitis) should prompt re-evaluation of the diagnosis.</li>\r\n<li><strong>MRI and CSF findings</strong> are critical in confirming MS, especially when clinical symptoms overlap with other neurological diseases.</li>\r\n</ul>",
      "correct_choice_id": 13,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-B, 3-C</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-A, 3-C</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-B, 3-A</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-C, 3-B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A final-year medical student observes three different cases of Multiple Sclerosis (MS) during his clinical rotation. His professor provides the descriptions in Column B and asks him to match each case with the correct type of MS from Column A.<br>Types of MS:<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106ce21f708-fe20-4e2e-9ba5-358e4d66e438.jpg\"></span></p>",
      "unique_key": "DT1295036",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295036,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Relapsing or Bout Onset MS (RMS) - Option A</strong>:\r\n<ul>\r\n<li>This form of MS is <strong>characterized by discrete attacks of neurologic dysfunction with recovery, but gradual progression over time</strong>. It represents the typical relapsing nature of MS, with attacks followed by partial or full recovery initially.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Secondary Progressive MS (SPMS) - Option B</strong>:\r\n<ul>\r\n<li>SPMS <strong>initially presents with relapsing episodes</strong> similar to RMS but eventually <strong>transitions into progressive disability without further attacks</strong>. This transition represents a change from episodic attacks to a progressive phase.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Primary Progressive MS (PPMS) - Option C</strong>:\r\n<ul>\r\n<li>PPMS is marked by a <strong>progressive decline in function from onset, with no acute attacks</strong>, and often has a <strong>later onset</strong> compared to other MS types. This steady progression without distinct episodes differentiates it from RMS and SPMS.</li>\r\n</ul>\r\n</li>  \r\n</ol>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Relapsing or Bout Onset MS (RMS)</strong>: Characterized by episodic attacks with recovery, which may lead to gradual progression.</li>\r\n<li><strong>Secondary Progressive MS (SPMS)</strong>: Starts with a relapsing course, then progresses continuously without further attacks.</li>\r\n<li><strong>Primary Progressive MS (PPMS)</strong>: Progressive functional decline from onset, typically without relapses, and seen in older age.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501064a6c83f8-99fe-47c8-8fd2-f33d7bf6e8da.jpg\">",
      "correct_choice_id": 24,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Living in a high-latitude region, history of infectious mononucleosis, and vitamin D deficiency</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Being Caucasian, following a low-fat diet, and using high-SPF sunblock</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Living in a tropical region, no history of EBV infection, and diet rich in leafy greens</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Being of African descent, residing in a temperate climate, and a history of severe childhood viral infections</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"> A 30-year-old Caucasian woman from northern Europe presents with a new episode of optic neuritis and paresthesias in her right leg. She has a history of cigarette smoking, reports minimal sun exposure, and follows a diet low in fatty fish. She also recalls having infectious mononucleosis during adolescence. Which of the following combinations of risk factors places her at the highest risk for developing Multiple Sclerosis (MS)?</span></p>",
      "unique_key": "DT1295044",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295044,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Living in a High-Latitude Region</strong>:\r\n<ul>\r\n<li>MS prevalence is significantly higher in high-latitude regions like northern Europe, North America, southern Australia, and New Zealand. These regions receive less UVB radiation, especially during winter months, leading to lower natural vitamin D synthesis and a higher MS risk.</li>\r\n</ul></li>\r\n<li><strong>History of Infectious Mononucleosis (EBV Infection)</strong>:\r\n<ul>\r\n<li>Epstein-Barr Virus (EBV) infection, particularly when contracted in adolescence or later, is a well-established risk factor for MS. Studies have shown a correlation between a history of infectious mononucleosis and increased MS susceptibility, although the causal relationship remains unproven.</li>\r\n</ul></li>\r\n<li><strong>Vitamin D Deficiency</strong>:\r\n<ul>\r\n<li>Vitamin D plays a crucial role in immune regulation. Deficiency is associated with a higher risk of developing MS and may increase disease activity in individuals with MS. Reduced sun exposure, use of sunblock, and low dietary intake of vitamin D-rich foods contribute to deficiency, particularly in high-latitude regions.</li>\r\n</ul></li>\r\n</ol>\r\n<p><strong>Option B</strong>: While some components are relevant (e.g., Caucasian ethnicity, high SPF use), a low-fat diet alone is not specifically linked to increased MS risk. Additionally, high SPF sunblock use alone doesn't fully explain vitamin D deficiency without low sun exposure or high latitude.</p>\r\n<p><strong>Option C</strong>: Living in a tropical region generally correlates with a lower risk of MS due to more sun exposure and less vitamin D deficiency. A diet rich in leafy greens is beneficial but lacks the high levels of vitamin D found in fatty fish.</p>\r\n<p><strong>Option D</strong>: Although persons of African descent can develop MS, they are at a relatively lower risk compared to Caucasians, especially in similar environments. Additionally, viral infections in childhood (other than EBV) have not shown a strong link with MS.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>High-Latitude Residency, Vitamin D Deficiency, and EBV Infection</strong> are critical risk factors for MS, especially in Caucasians.</li>\r\n<li><strong>Vitamin D synthesis from UVB exposure</strong> is limited in high-latitude regions, particularly in winter, increasing the risk.</li>\r\n<li><strong>Cigarette smoking and genetic factors</strong>, such as HLA-DRB1 gene association, also contribute significantly to MS susceptibility.</li>\r\n</ul>\r\n",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Sclerosis (MS)</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute Disseminated Encephalomyelitis (ADEM)</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Neuromyelitis Optica Spectrum Disorder (NMOSD)</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Progressive Multifocal Leukoencephalopathy (PML)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old woman presents with sudden, severe vision loss in both eyes and weakness in her legs. She reports a history of intractable nausea and vomiting lasting several weeks prior to her current symptoms. MRI reveals longitudinally extensive spinal cord lesions spanning three vertebral segments. Which of the following diagnoses is most likely?</span></p>",
      "unique_key": "DT1295061",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295061,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>NMOSD - Correct Diagnosis</strong>:\r\n<ul>\r\n<li><strong>Typical Presentation</strong>: NMOSD often presents with severe bilateral optic neuritis, leading to rapid and substantial vision loss. Other common symptoms include <strong>longitudinally extensive transverse myelitis</strong> (spinal cord inflammation spanning three or more vertebral segments) and intractable nausea or vomiting (due to area postrema involvement).</li>\r\n<li><strong>Antibody Confirmation</strong>: The presence of <strong>anti-AQP4 antibodies</strong> is highly specific for NMOSD and helps differentiate it from MS, where these antibodies are absent.</li>\r\n<li><strong>Key MRI Findings</strong>: Longitudinally extensive spinal cord lesions (&ge;3 vertebral segments) are characteristic of NMOSD and are less common in MS, which usually has shorter, patchier lesions.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Other Options:</strong></p>\r\n<ul>\r\n<li><strong>NMOSD</strong> is characterized by <strong>severe, bilateral optic neuritis</strong>, longitudinally extensive myelitis, and the presence of <strong>anti-AQP4 antibodies</strong>.</li>\r\n<li><strong>MS</strong> generally has shorter, patchier spinal lesions, perivenular demyelination, and a different immune profile involving <strong>autoreactive T cells</strong> targeting myelin proteins like MBP.</li>\r\n<li><strong>ADEM</strong> is monophasic, often post-infectious, and more common in children, with large, diffuse MRI lesions.</li>\r\n<li><strong>PML</strong> presents with asymmetrical white matter lesions and JC virus DNA, typically in immunocompromised patients.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106d95a027a-a28f-4bb3-974c-97e332d62915.jpg\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010675a377f5-0b11-4cbf-8796-af8942d6afd4.jpg\"><p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>MS</strong>: Relapsing course, periventricular lesions, oligoclonal bands in CSF.</li>\r\n<li><strong>ADEM</strong>: Monophasic, diffuse gray and white matter lesions, typically follows an infection.</li>\r\n<li><strong>NMOSD</strong>: Recurrent optic neuritis and transverse myelitis, anti-AQP4 antibodies are diagnostic.</li>\r\n<li><strong>PML</strong>: Progressive decline without relapses, JC virus DNA in CSF, seen in immunocompromised</li>\r\n</ul>\r\n",
      "correct_choice_id": 43,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">For a patient with 1 clinical attack and objective clinical evidence of 1 lesion, diagnosis of MS requires evidence of dissemination in space only, demonstrated by at least one T2 lesion in one of the MS-typical regions.</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">A patient with insidious neurologic progression suggestive of primary progressive MS (PPMS) requires at least 2 clinical attacks and objective evidence of lesions in both the brain and spinal cord for MS diagnosis.</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">For a patient with 2 or more clinical attacks and objective clinical evidence of 1 lesion, MS diagnosis requires dissemination in space, demonstrated by at least one T2 lesion in at least two MS-typical regions of the CNS.</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">For a patient with 1 clinical attack and objective clinical evidence of 2 or more lesions, MS diagnosis requires dissemination in time only, demonstrated by the presence of either gadolinium-enhancing and non-enhancing lesions at any time or a new T2 lesion on follow-up MRI.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements is correct according to the diagnostic criteria for Multiple Sclerosis (MS)?</span></p>",
      "unique_key": "DT1295064",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295064,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Correct Answer (Option C)</strong>:\r\n<ul>\r\n<li>If a patient has had <strong>2 or more clinical attacks</strong> but only <strong>1 lesion</strong> on examination, dissemination in space must be demonstrated for an MS diagnosis. This is confirmed by showing at least <strong>one T2 lesion in two of the four MS-typical regions</strong> (periventricular, juxtacortical, infratentorial, or spinal cord) or by waiting for a further clinical attack that implicates a different CNS site.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A</strong>: For a patient with <strong>1 clinical attack</strong> and <strong>1 lesion</strong> (clinically isolated syndrome), the diagnosis of MS requires evidence of <strong>dissemination in both space and time</strong>. Dissemination in space requires at least <strong>one T2 lesion in two of the MS-typical CNS regions</strong>, and dissemination in time can be shown by simultaneous asymptomatic gadolinium-enhancing and nonenhancing lesions or a new T2 lesion on follow-up MRI.</li>\r\n<li><strong>Option B</strong>: For PPMS, insidious neurologic progression over <strong>1 year</strong> is required, along with two out of three criteria: <strong>T2+ lesions in the brain (in MS-characteristic regions), T2+ lesions in the spinal cord</strong>, or <strong>positive CSF for oligoclonal bands or elevated IgG index</strong>. Clinical attacks are not a requirement in PPMS.</li>\r\n<li><strong>Option D</strong>: For a patient with <strong>1 clinical attack</strong> and <strong>2 or more lesions</strong>, MS diagnosis requires only <strong>dissemination in time</strong>. This can be demonstrated by the presence of both gadolinium-enhancing and non-enhancing lesions at any time, a new T2 lesion on follow-up MRI, or awaiting a second clinical attack.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501208d6b5fcc-d0d6-430f-98fa-1a2cbfa5b2cc.jpg\"><p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Multiple attacks</strong> and <strong>one lesion</strong> require <strong>dissemination in space</strong> for MS diagnosis.</li>\r\n<li><strong>One attack and one lesion</strong> (clinically isolated syndrome) require <strong>both dissemination in space and time</strong>.</li>\r\n<li><strong>PPMS</strong> diagnosis requires <strong>1 year of neurologic progression</strong> and dissemination in space in the brain or spinal cord, plus positive CSF findings.</li>\r\n</ul>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Binswanger's Disease</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Multiple Sclerosis</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">CADASIL</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">MELAS</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man presents with progressive gait difficulty, cognitive decline, and emotional disturbances. He also reports urinary incontinence. His family history is notable for several relatives with similar symptoms, and he recalls that his father and an uncle suffered from early strokes. MRI of the brain reveals multiple white matter lesions, particularly in the subcortical regions, without enhancement or mass effect. Laboratory tests show normal vitamin B12{12}12 levels and negative autoimmune markers. Genetic testing is pending. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295067",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295067,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Correct Answer (Option C - CADASIL)</strong>:\r\n<ul>\r\n<li><strong>Key Features</strong>: CADASIL is an autosomal-dominant disorder associated with <strong>mutations in the NOTCH3 gene</strong> and often presents with progressive <strong>gait difficulties, cognitive impairment, emotional disturbances</strong>, and a <strong>history of strokes</strong>.</li>\r\n<li><strong>Imaging Findings</strong>: The MRI in CADASIL typically shows <strong>subcortical white matter lesions</strong>, especially in the periventricular and anterior temporal lobes. The lesions do not enhance or show mass effect, which is consistent with this patient's findings.</li>\r\n<li><strong>Family History</strong>: CADASIL frequently has a family history of similar symptoms, with affected relatives experiencing strokes and cognitive decline at relatively young ages.</li>\r\n</ul>\r\n</li>  \r\n</ol>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (Binswanger's Disease)</strong>: Binswanger's Disease is a form of subcortical ischemic vascular dementia characterized by <strong>chronic hypertension</strong> and related white matter changes. Although it presents with cognitive decline and gait disturbance, it typically does not have a strong family history or autosomal-dominant inheritance pattern.</li>\r\n<li><strong>Option B (Multiple Sclerosis)</strong>: MS often presents with <strong>relapsing and remitting symptoms</strong> like optic neuritis, motor and sensory deficits, and upper motor neuron signs. MRI findings in MS show periventricular lesions, but MS is usually not associated with a family history of strokes or progressive cognitive decline.</li>\r\n<li><strong>Option D (MELAS)</strong>: MELAS presents with <strong>stroke-like episodes, seizures, lactic acidosis</strong>, and is typically associated with a mitochondrial inheritance pattern. MELAS does not present with urinary incontinence or progressive white matter lesions without stroke-like episodes and metabolic disturbances.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501066046c45a-e6fa-4016-a9cd-77d0ca0086f7.jpg\"><br><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010632aa22d7-3e16-4d9d-938e-4c9edb4f2903.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>CADASIL</strong>: An autosomal-dominant disorder due to NOTCH3 mutations, presenting with <strong>subcortical white matter lesions</strong>, progressive cognitive decline, mood disturbances, and often recurrent strokes.</li>\r\n<li><strong>Binswanger's Disease</strong>: Associated with chronic hypertension, typically lacks a strong family history of strokes, and primarily involves age-related white matter changes.</li>\r\n<li><strong>Multiple Sclerosis</strong>: Characterized by relapsing-remitting episodes with specific MRI patterns, usually lacking progressive cognitive impairment as a primary feature.</li>\r\n<li><strong>MELAS</strong>: Mitochondrial disorder presenting with stroke-like episodes, metabolic abnormalities, and seizures; it follows a maternal inheritance pattern.</li>\r\n</ul>",
      "correct_choice_id": 63,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-A, 3-C, 4-E, 5-D</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-B, 3-E, 4-D, 5-A</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">1-D, 2-C, 3-B, 4-A, 5-E</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-E, 3-C, 4-A, 5-D</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the Following: Newer Drugs and Their Mechanisms of Action or Notable Side Effects<br>Match each drug with its primary mechanism of action (MOA) or a notable adverse effect.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106e7cdeb82-2e2d-4a9c-ade6-e40e1dd22c90.jpg\"></span></p>",
      "unique_key": "DT1295070",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Alemtuzumab (1-B)</strong>:\r\n<ul>\r\n<li><strong>Mechanism</strong>: Alemtuzumab is a monoclonal antibody that targets <strong>CD52</strong> on T and B lymphocytes, leading to profound depletion of these immune cells.</li>\r\n<li><strong>Notable Side Effect</strong>: It is known for its potential to induce <strong>secondary autoimmune disorders</strong>, particularly <strong>autoimmune thyroid disease</strong>, as well as nephropathies and immune thrombocytopenia.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Siponimod (2-A)</strong>:\r\n<ul>\r\n<li><strong>Mechanism</strong>: Siponimod is a <strong>selective S1P receptor modulator</strong> similar to fingolimod but with selective activity at certain S1P receptors, reducing its cardiac risks.</li>\r\n<li><strong>Notable Side Effect</strong>: It is associated with <strong>macular edema</strong> as a side effect, particularly in patients with a history of uveitis or diabetes.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Cladribine (3-C)</strong>:\r\n<ul>\r\n<li><strong>Mechanism</strong>: Cladribine is an <strong>oral selective immunoreconstitution therapy</strong> that depletes lymphocytes, particularly T and B cells, through DNA synthesis inhibition.</li>\r\n<li><strong>Notable Side Effect</strong>: Increased <strong>risk of infections</strong> due to lymphocyte depletion is a major concern with cladribine, as well as potential malignancy risk.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Ozanimod (4-E)</strong>:\r\n<ul>\r\n<li><strong>Mechanism</strong>: Ozanimod is a next-generation <strong>S1P receptor modulator</strong> with a more selective profile than fingolimod, targeting S1P receptors 1 and 5, resulting in fewer cardiac side effects.</li>\r\n<li><strong>Notable Side Effect</strong>: Ozanimod has a lower incidence of bradycardia compared to fingolimod, making it safer for patients with cardiac issues.</li>\r\n</ul>\r\n</li>  \r\n<li><strong>Belimumab (5-D)</strong>:\r\n<ul>\r\n<li><strong>Mechanism</strong>: Belimumab is a <strong>monoclonal antibody against BAFF (B-cell activating factor)</strong>, used primarily in <strong>systemic lupus erythematosus (SLE)</strong> to reduce B-cell activation.</li>\r\n<li><strong>Notable Side Effect</strong>: It primarily affects B-cell function and is used specifically in SLE, with common adverse effects including nausea, diarrhea, and increased infection risk.</li>\r\n</ul>\r\n</li>  \r\n</ol>\r\n<p><strong>Key Takeaways</strong></p>\r\n<ul>\r\n<li><strong>Alemtuzumab</strong>: Targets CD52; notable for secondary autoimmune disorders, especially thyroid disease.</li>\r\n<li><strong>Siponimod</strong>: S1P receptor modulator with a lower cardiac risk profile; can cause macular edema.</li>\r\n<li><strong>Cladribine</strong>: Oral therapy for MS; depletes lymphocytes and increases infection risk.</li>\r\n<li><strong>Ozanimod</strong>: Next-generation S1P modulator with reduced bradycardia risk compared to fingolimod.</li>\r\n<li><strong>Belimumab</strong>: Targets BAFF receptor in B cells; primarily used in SLE.</li>\r\n</ul>",
      "correct_choice_id": 71,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">At least one core clinical characteristic must be optic neuritis, acute myelitis with longitudinally extensive transverse myelitis (LETM), or area postrema syndrome.</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Evidence of dissemination in space, defined as at least two different core clinical characteristics, is necessary for diagnosis.</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">A positive AQP4-IgG test result is essential for NMOSD diagnosis to distinguish it from Multiple Sclerosis (MS).</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Exclusion of alternative diagnoses is required to confirm the diagnosis of NMOSD without AQP4-IgG.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements regarding the diagnostic criteria for NMOSD (without AQP4-IgG or with unknown AQP4-IgG status) is incorrect?</span></p>",
      "unique_key": "DT1295072",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>A <strong>positive AQP4-IgG test</strong> <strong>is not required for the diagnosis of NMOSD</strong> if it is unknown or negative. For patients with negative or unknown AQP4-IgG status, NMOSD can still be diagnosed based on specific clinical criteria, MRI findings, and exclusion of alternative diagnoses. This differentiates it from MS and is particularly useful in cases where AQP4-IgG is undetectable or not tested.</p><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501064f414e82-2768-4b1b-9def-cda77b48f36e.jpg\"><p><strong>Correct Options: </strong></p>\r\n<p><strong>Option A</strong>: The diagnostic criteria for NMOSD require at least one core clinical characteristic, such as optic neuritis, LETM, or area postrema syndrome. This is an essential part of the NMOSD diagnosis.</p>\r\n<p><strong>Option B</strong>: Dissemination in space, involving at least two different core clinical characteristics, is necessary to support the diagnosis of NMOSD without AQP4-IgG.</p>\r\n<p><strong>Option D</strong>: Exclusion of alternative diagnoses is mandatory to confirm the NMOSD diagnosis in cases with negative or unknown AQP4-IgG, to avoid misdiagnosis with other demyelinating conditions like MS.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li>NMOSD Diagnosis: For NMOSD without AQP4-IgG or with unknown status, clinical criteria and MRI findings are used in the absence of AQP4-IgG.</li>\r\n<li>Core Characteristics: Optic neuritis, LETM, and area postrema syndrome are critical clinical features for NMOSD diagnosis.</li>\r\n<li>AQP4-IgG Testing: A positive AQP4-IgG is not essential for NMOSD diagnosis if the test is negative or unavailable.</li>\r\n</ul>",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Immediate IVIg or plasmapheresis</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Review of history for possible toxin exposure, family history, or systemic disease</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Test for paraprotein, HIV, and Lyme disease</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Consider surgery for nerve decompression</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old man presents with a history of progressive weakness and numbness in both legs over the past year. His nerve conduction studies (EDx) show an axonal polyneuropathy. He has no history of acute illness or significant exposures. Which of the following is the most appropriate next step in management?</span></p>",
      "unique_key": "DT1295073",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295073,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>For a <strong>chronic course (years)</strong> of axonal polyneuropathy, the next step in evaluation is a thorough <strong>review of the patient's history</strong> for any toxin exposure, systemic disease, or family history. Chronic axonal polyneuropathies can result from a variety of causes, including toxic exposures (e.g., alcohol, heavy metals), genetic factors, or systemic diseases (e.g., diabetes, renal disease).</p>\r\n<p><strong>Incorrect Options</strong>:</p>\r\n<ul>\r\n<li><strong>Option A (Immediate IVIg or plasmapheresis)</strong>: IVIg or plasmapheresis is typically indicated for <strong>acute demyelinating neuropathies</strong>, such as Guillain-Barr&eacute; Syndrome (GBS), or for chronic inflammatory demyelinating polyneuropathy (CIDP) if demyelination and conduction block are present. It is not generally used for chronic axonal polyneuropathy.</li>\r\n<li><strong>Option C (Test for paraprotein, HIV, and Lyme disease)</strong>: While these tests may be appropriate for subacute or demyelinating neuropathies, especially with a multifocal presentation, they are not the first step in the evaluation of a chronic axonal polyneuropathy.</li>\r\n<li><strong>Option D (Consider surgery for nerve decompression)</strong>: Surgical intervention is considered for <strong>entrapment neuropathies</strong> or compressive mononeuropathies, not for axonal polyneuropathies with a chronic progression in both legs.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Chronic axonal polyneuropathies</strong> often require a detailed review of patient history to identify potential systemic, genetic, or toxic causes.</li>\r\n<li><strong>IVIg or plasmapheresis</strong> is reserved for acute or demyelinating neuropathies, such as GBS or CIDP.</li>\r\n<li><strong>Surgical intervention</strong> is typically for mononeuropathies or compression neuropathies.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106fad7bdd0-f8c0-4ec4-ad70-261be87eb39b.jpg\">",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Amyotrophic Lateral Sclerosis (ALS)</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Multifocal Motor Neuropathy (MMN)</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Polyarteritis Nodosa (PAN)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 45-year-old woman presents with progressive asymmetric distal weakness in her right hand and foot, along with sensory loss in these areas. She reports no systemic illness, but has had mild weight loss recently. Physical examination reveals asymmetric weakness and reduced sensation in multiple nerves, but no upper motor neuron signs. Nerve conduction studies indicate multiple focal conduction blocks. Based on this presentation, which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295078",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295078,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p>CIDP can present with <strong>asymmetric distal weakness with sensory loss</strong> and often involves <strong>multiple nerves</strong>. In CIDP, nerve conduction studies may show <strong>conduction blocks</strong> due to demyelination, fitting this patient's findings.</p>\r\n<p><strong>Pattern in CIDP</strong>: This patient's symptoms align with <strong>Pattern 3</strong> (Asymmetric distal weakness with sensory loss) and multiple nerve involvement, which is often seen in multifocal variants of CIDP.</p>\r\n<p><strong>Incorrect Options: </strong></p>\r\n<p><strong>Option B (ALS)</strong>: ALS typically presents with both <strong>upper and lower motor neuron findings</strong> and does not have sensory loss. ALS is also usually symmetric and progressive, without focal conduction blocks.</p>\r\n<p><strong>Option C (Multifocal Motor Neuropathy - MMN)</strong>: MMN presents with <strong>asymmetric weakness</strong> but does not have sensory loss, as it primarily affects motor neurons. It also often presents with conduction block on nerve studies but would lack the sensory component found in this case.</p>\r\n<p><strong>Option D (Polyarteritis Nodosa - PAN)</strong>: PAN can cause <strong>mononeuritis multiplex</strong> with asymmetric weakness and sensory loss due to vasculitis affecting multiple nerves. However, conduction block on nerve studies is less common, and PAN is associated with systemic symptoms like fever, malaise, and organ involvement, which are absent in this case.</p>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>CIDP</strong>: Can present with <strong>asymmetric weakness and sensory loss</strong>, especially in multifocal variants, and may show <strong>conduction block</strong> on nerve studies.</li>\r\n<li><strong>ALS</strong>: Characterized by <strong>both upper and lower motor neuron signs</strong> without sensory loss.</li>\r\n<li><strong>MMN</strong>: Similar to ALS but typically asymmetric and limited to <strong>motor neurons</strong> without sensory involvement.</li>\r\n<li><strong>PAN</strong>: Causes <strong>mononeuritis multiplex</strong> but is typically associated with systemic symptoms and less frequently shows conduction blocks on nerve studies.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106a4071030-913a-4c60-a17e-92385d6be15f.jpg\">",
      "correct_choice_id": 101,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary demyelinating neuropathy</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Axonal neuropathy</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Hereditary demyelinating neuropathy</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Acquired demyelinating neuropathy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man presents with progressive weakness and numbness in his lower limbs. Nerve conduction studies reveal low-amplitude potentials with preserved distal latencies and conduction velocities. Needle EMG shows fibrillations. Which of the following is the most likely type of neuropathy?</span></p>",
      "unique_key": "DT1295084",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295084,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ol>\r\n<li><strong>Correct Answer (Axonal neuropathy)</strong>:\r\n<ul>\r\n<li><strong>Electrophysiologic Findings</strong>: In axonal neuropathies, nerve conduction studies typically show <strong>low-amplitude potentials</strong> with <strong>preserved distal latencies and conduction velocities</strong>. The presence of <strong>fibrillations on needle EMG</strong> is also suggestive of axonal damage, as these are signs of denervation.</li>\r\n<li><strong>Key Distinction</strong>: Axonal neuropathies primarily show loss of amplitude in nerve signals due to axonal loss rather than slowing of conduction.</li>\r\n</ul>\r\n</li>\r\n</ol>\r\n<p><strong>Incorrect Options</strong>:</p>\r\n<ul>\r\n<li><strong>Option A (Primary demyelinating neuropathy)</strong>: Demyelinating neuropathies are characterized by <strong>slow conduction velocities, prolonged distal latencies</strong>, and late potentials. Amplitudes are relatively preserved, and fibrillations are usually absent.</li>\r\n<li><strong>Option C (Hereditary demyelinating neuropathy)</strong>: In hereditary demyelinating neuropathies, like Charcot-Marie-Tooth (CMT) type 1, <strong>uniformly slow conduction velocities</strong> are typically observed, without conduction block or fibrillations.</li>\r\n<li><strong>Option D (Acquired demyelinating neuropathy)</strong>: Acquired demyelinating neuropathies, such as Guillain-Barre Syndrome (GBS) or CIDP, often show <strong>nonuniform slowing</strong>, conduction block, or temporal dispersion. Fibrillations are generally absent in purely demyelinating neuropathies.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Axonal neuropathy</strong>: Shows low-amplitude potentials, preserved conduction velocity, and fibrillations on EMG.</li>\r\n<li><strong>Primary demyelinating neuropathy</strong>: Characterized by slowed conduction velocities, prolonged distal latencies, and preserved amplitudes.</li>\r\n<li><strong>Hereditary demyelinating neuropathy</strong>: Uniform slowing of conduction velocities without conduction block.</li>\r\n<li><strong>Acquired demyelinating neuropathy</strong>: Nonuniform slowing, conduction block, or temporal dispersion; no fibrillations.</li>\r\n</ul>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Perform a lumbar puncture to assess cerebrospinal fluid (CSF) protein</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Order a skin biopsy to check for amyloid deposits</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Conduct an oral glucose tolerance test</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Check for antineuronal nuclear antibodies (e.g., anti-Hu antibodies)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 58-year-old woman presents with a 6-month history of painful sensory neuropathy and autonomic symptoms, including episodes of lightheadedness on standing and intermittent dry mouth. Her fasting blood glucose, HbA1c, and vitamin B12 {12}12 levels are normal. Nerve conduction studies (NCS) are normal, and an autonomic study reveals abnormal heart rate variability with deep breathing and blood pressure changes on tilt-table testing. Which of the following is the most appropriate next diagnostic step?</span></p>",
      "unique_key": "DT1295085",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295085,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<ul>\r\n<li><strong>Oral Glucose Tolerance Test</strong>: Patients with painful sensory neuropathy and normal fasting blood glucose and HbA1c may still have <strong>impaired glucose tolerance</strong>, which is detected in about one-third of cases with an oral glucose tolerance test. This test is particularly relevant in patients with small-fiber neuropathy and autonomic symptoms.</li>\r\n</ul>\r\n<p><strong>Incorrect Option</strong>:</p>\r\n<ul>\r\n<li><strong>Option A (Lumbar puncture)</strong>: Lumbar puncture for CSF protein is primarily useful in <strong>suspected cases of Guillain-Barre Syndrome (GBS) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</strong>, where elevated CSF protein without pleocytosis may be observed. It is not typically indicated for chronic, painless small-fiber neuropathies with autonomic involvement.</li>\r\n<li><strong>Option B (Skin biopsy)</strong>: Skin biopsy to check for amyloid deposits would be more relevant in patients suspected of <strong>amyloid neuropathy</strong>, characterized by painful sensory and autonomic symptoms. However, the clinical presentation and normal NCS do not suggest amyloidosis as the primary cause.</li>\r\n<li><strong>Option D (Antineuronal nuclear antibodies)</strong>: Anti-Hu antibodies are checked in cases of <strong>suspected paraneoplastic sensory ganglionopathy</strong>, especially in patients with severe sensory ataxia and risk of cancer. This is not the most appropriate test for this patient's presentation.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Small-fiber neuropathy</strong> with autonomic symptoms may warrant an <strong>oral glucose tolerance test</strong> even if fasting blood glucose and HbA1c are normal, as impaired glucose tolerance can contribute to neuropathy.</li>\r\n<li><strong>Lumbar puncture</strong> is indicated for suspected GBS or CIDP with high CSF protein.</li>\r\n<li><strong>Skin biopsy for amyloid</strong> is indicated for suspected amyloidosis but requires more specific clinical features.</li>\r\n<li><strong>Anti-Hu antibodies</strong> are relevant for <strong>paraneoplastic sensory ganglionopathy</strong>.</li>\r\n</ul>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Fabry's Disease</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Adrenoleukodystrophy</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Refsum's Disease</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Hereditary Sensory and Autonomic Neuropathy (HSAN)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old man presents with a history of burning pain in his hands and feet that began in his late teens. He reports reddish-purple skin lesions around his umbilicus and inguinal region. His medical history includes hypertension and progressive renal dysfunction. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295086",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295086,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Key Features</strong>: Fabry's disease presents with <strong>burning or lancinating pain in the extremities</strong> (typically starting in adolescence or early adulthood), <strong>angiokeratomas</strong> (reddish-purple maculopapular lesions commonly around the umbilicus, inguinal region, or perineum), and complications like <strong>hypertension, renal failure, cardiac disease, and stroke</strong> due to premature atherosclerosis.</p>\r\n<p><strong>Inheritance</strong>: It is an X-linked dominant disorder caused by mutations in the <strong>&alpha;-galactosidase gene</strong>, leading to the accumulation of <strong>ceramide trihexoside</strong> in nerves and blood vessels.</p>\r\n<p><strong>Incorrect Options</strong>:</p>\r\n<ul>\r\n<li><strong>Option B (Adrenoleukodystrophy)</strong>: ALD presents with CNS abnormalities, peripheral neuropathy, and adrenal insufficiency rather than angiokeratomas or burning pain in extremities.</li>\r\n<li><strong>Option C (Refsum's Disease)</strong>: Refsum's disease typically has a tetrad of <strong>peripheral neuropathy, retinitis pigmentosa, cerebellar ataxia, and elevated CSF protein</strong>, which were not present in this case.</li>\r\n<li><strong>Option D (Hereditary Sensory and Autonomic Neuropathy)</strong>: HSAN may cause sensory neuropathy but does not present with angiokeratomas, renal failure, or hypertension as seen in Fabry's disease.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501060f354b71-b8c8-4767-918e-3f5c1edbbce8.jpg\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501063317b593-99a5-426e-9f06-428ee0e95fcb.jpg\"><p><strong>KEY TAKEAWAYS:</strong></p>\r\n<p><strong>Fabry's Disease</strong> primarily affects males but can show symptoms in females. Neuropathy is overshadowed by atherosclerotic complications.</p>\r\n<p><strong>ALD/AMN</strong> patients have variable phenotypes, with neurological manifestations and adrenal insufficiency common in AMN.</p>\r\n<p><strong>Refsum's Disease</strong> requires dietary management to reduce phytanic acid levels and prevent progression of symptoms.</p>",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum very-long-chain fatty acid (VLCFA) levels</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum phytanic acid levels</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">&alpha;-galactosidase activity in leukocytes or cultured fibroblasts</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Antineuronal nuclear antibodies (anti-Hu antibodies)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year-old man with a family history of Fabry's disease presents with burning pain in his feet and hands. Physical examination reveals multiple reddish-purple skin lesions around his umbilicus. Which of the following diagnostic tests is most appropriate to confirm the diagnosis?</span></p>",
      "unique_key": "DT1295091",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295091,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Diagnosis of Fabry's Disease</strong>: Fabry's disease is diagnosed by measuring <strong>&alpha;-galactosidase activity</strong> in <strong>leukocytes or cultured fibroblasts</strong>. Decreased enzyme activity confirms the diagnosis, especially in males who are typically more severely affected due to the X-linked inheritance.</p>\r\n<ul>\r\n<li><strong>Pathophysiology</strong>: The deficiency in &alpha;-galactosidase activity leads to the accumulation of <strong>ceramide trihexoside</strong> in various tissues, causing the characteristic symptoms and complications of Fabry's disease.</li>\r\n</ul>\r\n<p><strong>Incorrect Options</strong>:</p>\r\n<ul>\r\n<li><strong>Option A (Serum VLCFA levels)</strong>: VLCFA levels are elevated in <strong>adrenoleukodystrophy (ALD)</strong>, not Fabry's disease.</li>\r\n<li><strong>Option B (Serum phytanic acid levels)</strong>: Phytanic acid levels are elevated in <strong>Refsum's disease</strong>, which presents with different clinical features.</li>\r\n<li><strong>Option D (Antineuronal nuclear antibodies)</strong>: Anti-Hu antibodies are associated with <strong>paraneoplastic sensory neuropathy</strong> and are not relevant to Fabry's disease.</li>\r\n</ul>\r\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106d4178fd5-ad1a-43e6-9213-26ebd54b1f90.jpg\"><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106696700a2-923b-48e3-bf41-894aabe6ab3d.jpg\">\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Fabry's Disease</strong>:\r\n<ul>\r\n<li>Clinical signs include <strong>burning pain in extremities</strong>, <strong>angiokeratomas</strong>, and complications like <strong>renal failure, hypertension, and cardiovascular disease</strong>.</li>\r\n<li><strong>Diagnosis</strong>: Confirmed by measuring <strong>&alpha;-galactosidase activity</strong> in leukocytes or fibroblasts.</li>\r\n<li><strong>Complications</strong>: Premature atherosclerosis leading to cardiovascular and renal complications is common.</li>\r\n</ul>\r\n</li>  \r\n</ul>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Refsum's Disease</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Tangier Disease</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Fabry's Disease</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Familial Amyloid Polyneuropathy (FAP)</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 40-year-old man presents with a history of slowly progressive numbness and tingling in his legs, especially in the lower limbs. On examination, he has asymmetric mononeuropathies and dissociated sensory loss with impaired pain and temperature perception in his arms but preserved position and vibration sense. Physical examination also reveals swollen, yellowish-orange tonsils. His lipid profile shows low HDL cholesterol levels and elevated triglycerides. Which of the following is the most likely diagnosis?</span></p>",
      "unique_key": "DT1295092",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295092,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Correct Answer (Tangier Disease)</strong>:</p>\r\n<ul>\r\n<li><strong>Key Features</strong>: Tangier disease is characterized by <strong>low HDL cholesterol</strong> and often presents with <strong>dissociated sensory loss</strong> (loss of pain/temperature sensation with preserved position/vibration), swollen yellowish-orange <strong>tonsils</strong>, and sometimes <strong>splenomegaly and lymphadenopathy</strong>.</li>\r\n<li><strong>Neuropathy Patterns</strong>: It can present with asymmetric mononeuropathies, symmetric polyneuropathy, or a pseudo-syringomyelia pattern with dissociated sensory loss, as seen in this patient.</li>\r\n</ul>\r\n<p><strong>Incorrect Options</strong>:</p>\r\n<ul>\r\n<li><strong>Option A (Refsum's Disease)</strong>: Refsum's disease typically presents with peripheral neuropathy, retinitis pigmentosa, cerebellar ataxia, and elevated CSF protein. It also involves high <strong>phytanic acid levels</strong>, not low HDL cholesterol.</li>\r\n<li><strong>Option C (Fabry's Disease)</strong>: Fabry's disease involves painful burning sensations in extremities, angiokeratomas, and renal and cardiac complications. There are no yellowish-orange tonsils or lipid abnormalities like low HDL.</li>\r\n<li><strong>Option D (Familial Amyloid Polyneuropathy - FAP)</strong>: FAP involves amyloid deposition with autonomic symptoms, cardiac involvement, and usually presents with painful sensory neuropathy rather than dissociated sensory loss.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Tangier Disease</strong>: Presents with low HDL cholesterol, dissociated sensory loss, swollen yellowish-orange tonsils, and sometimes splenomegaly or lymphadenopathy.</li>\r\n<li><strong>Porphyria</strong>: Characterized by neuropsychiatric symptoms, abdominal pain, hypertension, and brownish urine; diagnosis is confirmed with <strong>urinary porphyrin and porphobilinogen levels</strong>.</li>\r\n</ul>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum HDL cholesterol and triglyceride levels</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Serum phytanic acid levels</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">Urinary porphyrin and porphobilinogen levels</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Nerve biopsy showing amyloid deposits</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 35-year-old woman presents with abdominal pain, followed by episodes of agitation, hallucinations, and hypertension. She later develops weakness in her arms and legs, which is asymmetric and involves proximal muscles. Her urine appears brownish during sudden weakness. Which of the following tests is most likely to confirm the diagnosis?</span></p>",
      "unique_key": "DT1295096",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295096,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Urinary porphyrin and porphobilinogen levels</strong>:</p>\r\n<ul>\r\n<li><strong>Key Features of Porphyria</strong>: This patient's <strong>abdominal pain, neuropsychiatric symptoms (agitation, hallucinations)</strong>, <strong>hypertension</strong>, and <strong>asymmetric proximal weakness</strong> are classic for <strong>acute intermittent porphyria</strong> (AIP) or other forms of acute porphyrias. <strong>Brownish urine</strong> due to high levels of porphyrin metabolites during attacks is also a typical feature.</li>\r\n<li><strong>Diagnosis</strong>: Elevated levels of <strong>porphyrin precursors</strong> like <strong>porphobilinogen and delta-aminolevulinic acid</strong> in urine confirm the diagnosis.</li>\r\n</ul>\r\n<p><strong>Incorrect</strong> Options:</p>\r\n<ul>\r\n<li><strong>Option A (Serum HDL cholesterol and triglyceride levels)</strong>: Low HDL cholesterol and high triglycerides are indicative of <strong>Tangier disease</strong>, which does not typically present with neuropsychiatric symptoms or brown urine.</li>\r\n<li><strong>Option B (Serum phytanic acid levels)</strong>: Elevated phytanic acid is diagnostic for <strong>Refsum's disease</strong>, which is associated with peripheral neuropathy and retinitis pigmentosa, not acute neuropsychiatric or abdominal symptoms.</li>\r\n<li><strong>Option D (Nerve biopsy showing amyloid deposits)</strong>: This is relevant to <strong>Familial Amyloid Polyneuropathy (FAP)</strong>, which does not typically present with acute attacks or urinary color changes.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Tangier Disease</strong>: Presents with low HDL cholesterol, dissociated sensory loss, swollen yellowish-orange tonsils, and sometimes splenomegaly or lymphadenopathy.</li>\r\n<li><strong>Porphyria</strong>: Characterized by neuropsychiatric symptoms, abdominal pain, hypertension, and brownish urine; diagnosis is confirmed with <strong>urinary porphyrin and porphobilinogen levels</strong>.</li>\r\n</ul>",
      "correct_choice_id": 163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">1-A, 2-B, 3-C</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-B, 3-A</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">1-B, 2-C, 3-A</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">1-C, 2-A, 3-B</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following clinical cases (List A) with the most likely diagnosis (List B):<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/202501062d0b386b-fbae-48b1-9850-41fd04af13fd.jpg\"><br>Select the correct match:</span></p>",
      "unique_key": "DT1295104",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295104,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010654f3f3d0-a557-4788-98ad-9cc5f5865d07.jpg\"><br><p><strong>Summary of Selected Hereditary and Metabolic Neuropathies</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010603bc3ccd-dceb-4280-9c23-b12970219ce6.jpg\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/2025010678b44a5c-e1e0-4293-9d57-4b4f7bccac33.jpg\">",
      "correct_choice_id": 172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">GBS commonly recurs in most patients within five years.</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Recurrence is rare, occurring in less than 5% of patients.</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">You are at high risk for recurrence due to your age.</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Plasmapheresis increases the risk of GBS recurrence.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man is recovering from Guillain-Barre Syndrome (GBS) and is concerned about the possibility of recurrence. Which of the following statements is most appropriate to share with the patient regarding recurrence risk?</span></p>",
      "unique_key": "DT1295106",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295106,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Recurrence in GBS</strong>: Recurrence of Guillain-Barre Syndrome is rare, with studies showing that less than 5% of patients experience a second episode. Most cases of GBS are monophasic, meaning they occur as a single episode and do not recur.</p>\r\n<p><strong>Reassurance</strong>: This information is reassuring for patients who are concerned about the likelihood of recurrence.</p>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (\"GBS commonly recurs in most patients within five years\")</strong>: This is incorrect because GBS recurrence is uncommon. Most patients experience only one episode, and the majority do not have recurrent attacks within five years.</li>\r\n<li><strong>Option C (\"You are at high risk for recurrence due to your age\")</strong>: Age is not a known risk factor for GBS recurrence. Recurrence, when it does occur, is not correlated with age.</li>\r\n<li><strong>Option D (\"Plasmapheresis increases the risk of GBS recurrence\")</strong>: Plasmapheresis (plasma exchange) is a treatment for GBS and does not increase the risk of recurrence. In fact, it is used to shorten the course of illness in the acute phase.</li>\r\n<li><strong>Option E (\"You should avoid all vaccinations to prevent recurrence\")</strong>: Vaccinations do not generally increase the risk of GBS recurrence. However, in patients with a history of GBS following a specific vaccine, healthcare providers may recommend avoiding that particular vaccine or spacing out vaccinations. Routine vaccinations are often safe, with timing adjustments made on a case-by-case basis.</li>\r\n</ul>\r\n<p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>GBS Recurrence</strong>: Recurrence of GBS is rare, affecting less than 5% of patients. Most patients experience GBS as a single, non-recurrent episode.</li>\r\n<li><strong>Vaccinations</strong>: Vaccinations are generally safe, but specific guidelines should be followed, especially for vaccines previously associated with GBS.</li>\r\n<li><strong>Plasmapheresis</strong>: This treatment does not increase recurrence risk and is beneficial in managing acute GBS.</li>\r\n</ul>",
      "correct_choice_id": 182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">High-dose corticosteroids are the first-line treatment</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Corticosteroids shorten the recovery time when used with IVIG</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Corticosteroids are ineffective and not recommended</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral corticosteroids are preferred over intravenous forms</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following statements about the use of corticosteroids in Guillain-Barre Syndrome (GBS) is most accurate?</span></p>",
      "unique_key": "DT1295109",
      "question_audio": null,
      "question_video": null,
      "map_id": 1295109,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Evidence in GBS Treatment</strong>: Numerous studies have shown that <strong>corticosteroids do not improve outcomes in Guillain-Barr&eacute; Syndrome</strong>. Corticosteroids neither reduce the recovery time nor improve neurological function in GBS patients. Consequently, they are <strong>not recommended</strong> as part of the treatment regimen.</p>\r\n<p><strong>Preferred Treatments</strong>: The first-line treatments for GBS are <strong>IV immunoglobulin (IVIG)</strong> and <strong>plasmapheresis</strong>. These therapies help reduce the immune-mediated attack on the peripheral nerves and have been shown to improve recovery times and reduce the severity of symptoms.</p>\r\n<p><strong>Incorrect Options:</strong></p>\r\n<ul>\r\n<li><strong>Option A (High-dose corticosteroids as first-line treatment)</strong>: High-dose corticosteroids are not the standard treatment for GBS, as they do not provide benefit in GBS and are therefore not used as first-line therapy.</li>\r\n<li><strong>Option B (Corticosteroids shorten recovery with IVIG)</strong>: Adding corticosteroids to IVIG does not shorten recovery time. Studies have not shown an additive benefit when corticosteroids are used alongside IVIG.</li>\r\n<li><strong>Option D (Oral corticosteroids over intravenous forms)</strong>: Since corticosteroids are generally ineffective in GBS, neither oral nor intravenous corticosteroids are preferred.</li>\r\n<li><strong>Option E (Corticosteroids prevent respiratory failure)</strong>: Corticosteroids do not prevent respiratory failure in GBS patients. Respiratory failure is managed with <strong>supportive care and early monitoring</strong> of pulmonary function, with IVIG or plasmapheresis to treat the underlying immune response.</li>\r\n</ul>\r\n<h3><strong>Management of GBS</strong></h3><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V3/NEETPGMCQ/20250106f8bfbc42-86d7-4fff-8b9e-f8e015bd1f34.jpg\"><p><strong>Key Takeaways:</strong></p>\r\n<ul>\r\n<li><strong>Corticosteroids</strong> are ineffective in treating GBS and are therefore not recommended.</li>\r\n<li><strong>First-line therapies</strong> for GBS include <strong>IVIG</strong> and <strong>plasmapheresis</strong>, which help by modulating the immune response.</li>\r\n<li>Corticosteroids do not prevent complications or shorten recovery time in GBS.</li>\r\n</ul>",
      "correct_choice_id": 193,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}